Cargando…
Feasibility and safety of cCD20 RNA CAR-bearing T cell therapy for the treatment of canine B cell malignancies
Autores principales: | Smith, Jenessa B, Panjwani, M Kazim, Schutsky, Keith, Gnanandarajah, Josephine, Calhoun, Sondra, Cooper, Laurence, Mason, Nicola, Powell, Daniel J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4646055/ http://dx.doi.org/10.1186/2051-1426-3-S2-P123 |
Ejemplares similares
-
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
por: Schutsky, Keith, et al.
Publicado: (2015) -
IMMU-20. EVALUATION OF CAR T CELLS IN EPENDYMOMA
por: Nellan, Anandani, et al.
Publicado: (2020) -
A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial
por: Gnanandarajah, Josephine S, et al.
Publicado: (2014) -
High affinity FRβ-specific CAR T cells eradicate AML and normal yeloid lineage without HSC toxicity
por: Lynn, Rachel C, et al.
Publicado: (2016) -
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma
por: Panjwani, M. Kazim, et al.
Publicado: (2019)